Rheumatologists typically manage systemic autoimmune rheumatic diseases (SARD) and associated interstitial lung disease (ILD) with immunosuppressants. However, evidence increasingly supports also the use of antifibrotic agents in this setting.
Read Article
Dr. Assassi is Director of the Division of Rheumatology and Professor of Medicine at UTHealth Houston. He also co-directs the UTHealth Scleroderma Program, which houses one of the largest specialized systemic sclerosis clinics in the USA. His laboratory focuses on the molecular profiling of longitudinally collected biospecimens for the identification of novel therapeutic targets and biomarkers. He is also a Steering Committee Member of several multicenter, international clinical trials focusing on the treatment of systemic sclerosis or SARD-ILDs.
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
